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Abstract 
Objective Therapeutically targeting lymphocyte adhesion is of increasing relevance 
in IBD. Yet, central aspects of the action of anti-adhesion compounds are 
incompletely understood. We investigated the role of αEβ7 and α4β7 integrins and 
their blockade by vedolizumab and etrolizumab for trafficking of IBD T lymphocytes in 
an in vivo model of homing to and retention in the inflamed gut. 
Design We explored integrin expression in IBD patients by flow cytometry and 
immunohistochemistry, while regulation of integrins was studied in T cell cultures. 
The functional relevance of integrins was assessed by adhesion assays and a 
recently established humanized mouse model in DSS-treated immunodeficient mice. 
Results High expression of αEβ7 was noted on CD8+ and CD4+ Th9 cells, while 
α4β7 was expressed on CD8+, Th2 and Th17 cells. TCR stimulation and TGF-β were 
key inducers of αEβ7 on human T cells, while butyric acid suppressed αEβ7. In 
comparison to α4β7 blockade via vedolizumab, blockade of β7 via etrolizumab 
surrogate antibody superiorly reduced colonic numbers of CD8+ and Th9 cells in vivo 
after 3 hours, while no difference was noted after 0.5 hours. AEβ7 expression was 
higher on CD8+ T cells from IBD patients under vedolizumab therapy. 
Conclusion AEβ7 is of key relevance for gut trafficking of IBD CD8+ T cells and 
CD4+ Th9 cells in vivo and mainly retention might account for this effect. These 
findings indicate that blockade of αEβ7 in addition to α4β7 may be particularly 
effective in intestinal disorders with expansion of CD8+ and Th9 cells such as IBD. 
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What is already known about the subject? 
 The α4β7 integrin antibody vedolizumab blocks gut homing of regulatory and 
effector CD4+ T cells and is successfully used for clinical therapy in IBD 
 αEβ7 integrin is believed to mediate retention of lymphocytes in or near the 
epithelium via interaction with E-Cadherin 
 The β7 integrin antibody etrolizumab targets α4β7 and αEβ7 integrins and is 
currently evaluated in phase III trials 
 
What are the new findings? 
 αEβ7 and α4β7 are differentially expressed on human T lymphocytes both in 
the peripheral blood and the intestine 
 TCR stimulation and TGF-β treatment increase αEβ7 expression especially on 
CD8+ lymphocytes 
 Etrolizumab surrogate antibody blocks adhesion of T lymphocytes to 
MAdCAM-1 and E-Cadherin in vitro 
 In a recently established humanized mouse model, etrolizumab surrogate 
antibody is more potent than vedolizumab in reducing accumulation of human 
CD8+ and CD4+ Th9 cells in the inflamed gut, probably due to additional 
inhibition of αEβ7-mediated retention 
 
How might it impact on clinical practice in the foreseeable future? 
β7 inhibition by antibodies such as etrolizumab might offer additional benefits for the 
treatment of IBD compared with α4β7 inhibition 
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Introduction 
 
A dysguided inflammatory response within the intestinal lamina propria is believed to 
be a cornerstone of the pathogenesis of inflammatory bowel diseases (IBD) such as 
ulcerative colitis (UC) and Crohn’s disease (CD) [1–3]. In particular, CD4+ and CD8+ 
T lymphocytes are critically involved in the responsible immunologic network by 
secreting pro-inflammatory cytokines, orchestrating the function of other immune 
cells and causing direct damage to cellular or extracellular elements of the intestinal 
wall [4–6].  
Naïve T-lymphocytes are primed to become gut homing lymphocytes in the mucosa 
associated lymphoid tissue (MALT). Here, dendritic cells (DCs) not only function as 
antigen presenting cells, but also induce the expression of α4β7 integrin via 
production of retinoic acid [7,8]. After reentering the circulation thus primed 
lymphocytes are able to access the intestinal lamina propria in a complex homing 
process [9] that critically involves the interaction of α4β7 integrin with its endothelial 
receptor mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), which is 
exclusively expressed on postcapillary venules in the intestine [10]. 
Blockade of α4β7 integrin-mediated gut homing with vedolizumab has greatly 
increased the options in clinical therapy of patients with IBD [11,12]. Mechanistically, 
we have recently shown, that vedolizumab reduces colonic homing of both effector 
and regulatory CD4+ T lymphocytes [13]. However, the impact of vedolizumab on 
CD8+ T cells and cytokine-producing CD4+ T lymphocyte subsets has not been 
addressed so far. Moreover, lymphocyte homing can potentially be mediated by other 
homing molecules like α4β1 integrin as well [14] suggesting that vedolizumab may 
not suppress homing of all lymphocyte subsets. Consistent with this concept 
vedolizumab does not induce or maintain remission in a significant portion of patients 
[11,12]. 
Several other compounds interfering with the gut homing process are currently under 
development. One of them is the monoclonal humanized rat anti-β7 integrin antibody 
etrolizumab, which has recently successfully been tested in a phase II study [15]. As 
anti-β7 antibody, it not only interferes with the interaction of α4β7 with MAdCAM-1, 
but also inhibits binding of αEβ7 to its receptor E-Cadherin. As E-Cadherin is mainly 
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expressed on epithelial cells, its ligand αEβ7 is believed to mediate epithelial 
retention of homed gut lymphocytes [16] such as intraepithelial lymphocytes (IEL) 
[17]. Moreover, a decrease in the number of αE+ cells in the intestinal crypt 
epithelium was associated with a therapeutic response to etrolizumab treatment [15]. 
Yet, functional in vivo studies assessing the importance of αEβ7 for trafficking of 
lymphocytes are lacking and the abilities of α4β7 versus β7 blockade to reduce 
lymphocyte accumulation in IBD have not been compared to date. Here, we explored 
homing and retention of human IBD CD4+ and CD8+ T cells upon α4β7 blockade via 
vedolizumab and β7 blockade via etrolizumab surrogate antibody in a humanized 
mouse model of colitis. Our findings indicate that etrolizumab has marked additional 
effects on CD8+ and Th9 trafficking compared with vedolizumab and might be a 
useful tool for future clinical therapy in IBD.  
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Methods 
 
IBD patients 
Peripheral blood and gut samples from patients with CD (n = 120) and UC (n = 74) 
were collected after informed written consent according to the approval of the local 
Ethics Committee. Blood and tissue specimens from healthy donors and tumor 
patients served as controls (n = 61), respectively. Gut samples of IBD patients came 
from areas of active disease. Blood from patients receiving vedolizumab was 
collected during (i.e. infusions at weeks 0, 2 and 6) or after (i.e. later infusions from 
week 14 on) the induction phase of vedolizumab therapy. Supplementary table 1 
summarizes the patients’ clinical data. 
 
Cell isolation and stimulation 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation with Pancoll (Pan Biotech). CD4+ or CD8+ cells were isolated with 
immunomagnetic beads (Miltenyi Biotec). Where indicated, cells were cultured in 
RPMI 1640 medium (Gibco) with 10 % FCS (Pan Biotech) and 1 % 
penicillin/streptomycin (Biochrom) or X-Vivo medium (Lonza) with 1 % 
penicillin/streptomycin and stimulated with precoated anti-human CD3 (OKT3, 
eBioscience) and 1 µg/mL anti-human CD28 (CD28.2, BD) antibodies.  
Where indicated, cells were treated with the following recombinant human cytokines 
for 72 hours: IL-1β, IL-2, IL-4, IL-6, IL-7 (all from Immunotools), IL-9 (Peprotech), IL-
12 (all 10 ng/mL), IFN-γ (100 ng/mL, both from Immunotools) and TGF-β (20 ng/mL, 
R&D Systems). Moreover, cells were treated with CCL-25 (Immunotools), retinoic 
acid (Cayman Chemical), butyric acid (Roth), isobutyric acid (abcr), formic acid 
(Merck) and propionic acid (Roth).  
For some CCL-25 stimulation experiments, CD4+CCR9+ and CD8+CCR9+ cells were 
purified by FACS (FACS Aria, BD). 
 
Flow cytometry 
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For flow cytometric analyses, human cells were incubated with antibodies against 
CD4 (APC/Cy7,RPA-T4), CD8 (FITC, RPA-T8; PE, HIT8a; AF647, SK1), β7 integrin 
(PerCP/Cy5.5 and PE, FIB27), αE integrin (PE/Cy7, Ber-Act8), IFN-γ (AF700, 
4S.B3), IL-4 (AF488, 8D4-8), IL-9 (AF647, MH9A4), IL-17A (BV605, BL168, all from 
Biolegend), α4 (VioBlue, MZ-18-24A9, Miltenyi), Foxp3 (PE, 236A/E7, eBioscience) 
and appropriate isotype-matched control antibodies. In some experiments, 
vedolizumab (Takeda) and etrolizumab surrogate antibody (FIB504, Genentech) 
were directly labeled with AF488 and AF647, respectively (Thermo Fisher). For 
intracellular staining cells were treated with the Foxp3/Transcription Factor Staining 
Buffer Set (eBioscience). Analyses were performed on LSR Fortessa instruments 
(BD). For identification of T cell subsets PBMCs were restimulated with PMA and 
ionomycin (Sigma Aldrich) together with transport inhibition by brefeldin A 
(Biochemica) for four hours. 
 
Immunohistochemistry 
Cryosections were fixed with 4 % paraformaldehyde and blocked with avidin/biotin 
blocking reagent (Vector Laboratories) and protein-blocking reagent (Roth). The 
sections were incubated with antibodies against CD4 (RPA-T4), CD8 (RPA-T8, both 
BD; polylonal, abcam), E-Cadherin (36/E, BD), Foxp3 (236A/E7, eBioscience), αE 
integrin (ab129202, Abcam), CD11c (BU15, AbD Serotec), CD69 (FN50, BD), CD123 
(6H6, eBioscience), CD141 (Qbend/40, AbD Serotec), vedolizumab and etrolizumab 
surrogate followed by fluorescent- or biotin-labeled secondary antibodies (Vectorlabs 
and Merck). If applicable, slides were treated with Dylight488- or Cy3-conjugated 
streptavidin (Biolegend). Nuclei were counterstained with Hoechst reagent (molecular 
probes) and samples were analyzed by fluorescence confocal microscopy (LSM SP8, 
Leica). Single and double positive cells in at least three high power fields were 
counted.  
 
MAdCAM-1/E-Cadherin adhesion assay 
Adhesion assays were performed as described previously [13,18] on epoxy-coated 
glass slides (Neolab). Wells were coated with Fc chimera of rhMAdCAM-1, rhE-
Cadherin or rmE-Cadherin (all 5 µg/mL, all from R&D) in 150 mM NaCl with 20 mM 
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HEPES (AMRESCO) at 37 °C overnight followed by blocking with 5 % BSA at 37 °C 
for two hours. 200,000 purified CD4+ or CD8+ cells in adhesion buffer [18] were 
added for 90 minutes at 37 °C. After washing, adherent cells were counterstained 
with Hoechst. In blocking experiments, cells were preincubated with 5 µg/mL anti-αE 
integrin (Ber-Act8, Biolegend), 100 µg/mL vedolizumab or 5 µg/mL of the etrolizumab 
surrogate antibody rat anti-human/mouse β7 integrin for two hours. Etrolizumab is 
the humanized version of the latter antibody with the identical antigen recognition 
site, but is only available in clinical trials at the moment and could thus not be used. 
Mouse anti-human IgG1 and rat anti-human/mouse IgG2a (both Biolegend) were 
used as isotype controls for vedolizumab and etrolizumab surrogate, respectively, 
where indicated. Finally, slides were analyzed by fluorescence and confocal 
microscopy and adherent cells in at least three high power fields per condition were 
counted. Values are presented normalized to the respective untreated condition.  
 
Proliferation and apoptosis assay 
Human PBMCs were stained with CellTrace Violet cell proliferation kit (Life 
technologies) and stimulated for 72 hours. Afterwards, cells were stained with 
Annexin V (FITC, Biolegend), Propidiumiodide (eBioscience) and antibodies against 
CD4 and CD8 before flow cytometric analysis.  
 
Humanized mouse model of in vivo homing and retention to the inflamed gut 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) and RAG1-deficient (B6 RAG1-/-) mice 
lacking native lymphocytes were housed in individually ventilated cages and used for 
experiments according to the approval of the Government of Lower Franconia. 
Dextran sodium sulfate (DSS) colitis and adoptive transfer experiments were 
performed as recently described [13]. Two million cells of the indicated type were 
labeled with CFSE (Life technologies) and treated with 5 µg/mL anti-αE integrin, 100 
µg/mL vedolizumab or 5 µg/mL FIB504 overnight, where specified. Mice were 
anesthetized with ketamine/xylazine by intraperitoneal injection. Subsequently, 
Hoechst dye was injected to the tail vein for murine cell staining. CFSE-labeled cells 
and Texas Red Dextran (Life technologies) for vessel staining were injected into the 
ileocolic artery guided by a stereomicroscope (Zeiss). For in vivo imaging, the colon 
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was longitudinally opened and the mucosa positioned on a glass transparent petri 
dish for intravital analysis with an SP8 confocal microscope (Leica).  
For flow cytometric analyses, mice were sacrificed 0.5 or 3 hours after adoptive 
transfer and T cell enriched lamina propria mononuclear cells (LPMCs) were isolated 
using the lamina propria isolation kit (Miltenyi Biotec). The CFSE+ fraction was 
quantified by flow cytometry. For further characterization of CD4+ cells LPMC aliquots 
were stained for αEβ7 and the transcription factors T-bet (BV605, 4B10, Biolegend), 
ROR-γt (PE, REA278, Miltenyi), PU.1 (AF647, 7C6B05, Biolegend).  
 
Statistics 
Statistical differences were identified using ANOVA or student’s t-test where 
applicable in Graph Pad Prism (Graph Pad Software). Levels of significance are 
indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001). Graphs display means 
with SEM indicated by error bars.  
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Results 
 
AEβ7 and α4β7 integrins are differentially expressed on T cell subsets in the 
peripheral blood of IBD patients 
Although it is known that αEβ7 integrin is expressed on a subset of peripheral T cells 
[17], no quantitative analysis of αEβ7 expression in IBD has been performed so far. 
Moreover, αEβ7 and α4β7 expression on cytokine-producing lymphocyte subsets is 
largely unknown. We therefore measured the expression of αEβ7 and α4β7 on CD4+ 
and CD8+ T cells in patients with UC, CD and control donors. We found a significantly 
higher expression of αEβ7 and α4β7 on CD8+ than on CD4+ T cells regardless of the 
group analyzed (Fig. 1A, Suppl. Fig. 1A+B). Furthermore, α4β7 levels on UC CD8+ T 
cells were found to be significantly higher than on CD CD8+ T cells suggesting a 
particular relevance of this integrin for CD8+ T cell homing in the former disease. To 
define the potential differential target cells for vedolizumab and etrolizumab in the 
peripheral blood more clearly, we analyzed α4 expression on αEβ7+ cells and found 
that many of these cells also bore α4 (Suppl. Fig. 1C), thus formally expressing both 
α4β7 and αEβ7, although co-expression of α4β1 and αEβ7 might also lead to this 
picture. Therefore, we directly labeled vedolizumab and an etrolizumab surrogate 
antibody with the identic antigen recognition site and used these antibodies in flow 
cytometry. While the majority of cells was stained by both labelled vedolizumab and 
etrolizumab, we were able to detect a small subset of T lymphocytes that was 
targeted by etrolizumab but not vedolizumab and this subset was significantly larger 
in CD8+ than in CD4+ cells (Suppl. Fig. 1D). 
Next, we quantified the expression of αEβ7 on CD4+ T cell subsets (Fig. 1B, Suppl. 
Figs 1E, F). While Treg cells and overall Teff cells had low levels of αEβ7, the 
expression was markedly increased on Th17 and Th9 cells with the highest levels on 
Th9 cells. No differences between UC, CD and controls were noted. With regard to 
the expression of α4β7, Th2 and Th17 cells showed particularly high expression, 
while levels on Treg, Th1 and Th9 cells were lower. With the exception of a higher 
α4β7 expression on Th9 cells from CD than controls, α4β7 levels on the different 
subsets in UC, CD and controls were similar (Suppl. Fig. 1G). 
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In CD8+ T cell subsets [19], we detected no significant differences of α4β7 levels 
between different groups (Suppl. Figs. 1H, I). However, IL-9 secretion was correlated 
with a high expression of αEβ7, while Tc2 cells expressed particularly low levels of 
αEβ7. Additionally, we found that Tc17 cells from CD patients expressed more αEβ7 
than Tc17 cells from controls and UC. Taken together, these findings supported the 
notion that αEβ7 and α4β7 are differentially expressed on various T cell subsets 
suggesting that anti-adhesive therapies may not equally block adhesion of all 
lymphocyte subsets in IBD. 
 
High expression of αEβ7 on intestinal CD4+ and CD8+ T lymphocytes in IBD 
In subsequent studies, we explored the expression of αEβ7 on intestinal lymphocytes 
in IBD by immunohistochemistry. We observed that both in CD and UC the 
percentage expression of αEβ7 on CD4+ T cells is higher than in controls and 
exceeds 10 %, therefore being markedly higher than in the peripheral blood (Figs 2A, 
D, Suppl. Fig. 2A). However, the expression of αEβ7 on Foxp3+ cells in the lamina 
propria was unchanged in samples from CD and UC compared with controls (around 
5 %; Figs 2B, D, Suppl. Fig. 2B), suggesting that mucosal Treg cells might be a 
population with particularly low expression of αEβ7. 
The αEβ7 expression on CD8+ cells in the gut markedly differed between CD8+ cells 
in the lamina propria and the epithelium (Figs 2C, D, Suppl. Fig. 2C). However, the 
expression did not significantly vary between controls, UC and CD. Overall, αEβ7 
was expressed by around 40 % of the CD8+ lymphocytes, thus on a remarkably 
greater fraction than in the peripheral blood. Again, the differential expression of 
αEβ7 on CD4+ and CD8+ lymphocytes highlighted the idea that therapeutically 
blocking this integrin might have different effects on lymphocyte subpopulations. 
To further explore the nature of these CD8+αEβ7+ cells in the intestine, we performed 
additional stainings with the T resident memory (TRM) cell marker CD69 [20]. We 
found that around 40 % of the CD103+ cells also expressed CD69, roughly equaling 
the frequency of CD8 expression among CD103+ cells (Suppl. Fig. 2D) and thus 
suggesting that the majority of CD8+αEβ7+ T lymphocytes are TRM cells. Moreover, 
we sought to exclude that dendritic cells (DCs) add to the CD8+αEβ7+ population as 
both CD8 and αEβ7 are potential markers of DC subsets [21]. As expected, we 
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identified αEβ7+ DCs using the pan-DC marker CD11c [22] (Suppl. Fig. 2E). 
However, almost no CD11c+ cell co-expressed CD8 (Suppl. Fig. 2F). To additionally 
cover DC subsets with lower CD11c expression, we also used CD123 and CD141 as 
markers for plasmocytoid DCs and type II classical DCs, respectively [22]. In these 
subsets, the co-expression of αEβ7+ was very low (Suppl. Figs. 2G, H). Thus, if at all, 
the contribution of CD8+αEβ7+ DCs to the overall CD8+αEβ7+ population seems 
infinitesimal and the vast majority of these cells are T lymphocytes.  
The high expression of αEβ7 on CD4+ and CD8+ lymphocytes in the intestinal 
mucosa compared with the peripheral blood was consistent with the idea that αEβ7 
might be induced on both CD4+ and especially CD8+ lymphocytes upon reaching the 
intestinal mucosa. However, we also considered that this finding might be due to 
accumulation of these cells following preferential homing. To address this, we 
performed another series of stainings with vedolizumab and etrolizumab surrogate 
antibody (Suppl. Fig. 2I). As expected, virtually all vedolizumab+ cells were also 
etrolizumab+ but in contrast to the peripheral blood a relevant single etrolizumab+ 
population could be identified. As this is markedly different from the pattern in the 
peripheral blood (Suppl. Fig. 1D), it strongly suggested that indeed regulation of 
integrin expression is responsible for the differential integrin levels in the peripheral 
blood and the intestine. Moreover, these experiments proved that targeting β7 
instead of α4β7 increases the number of target cells not only in the blood but also in 
the gut. 
 
TGF-beta and butyric acid are key regulators of αEβ7 expression on CD4+ and 
CD8+ T lymphocytes  
To further elucidate the mechanisms controlling αEβ7 upregulation in the intestinal 
mucosa, we studied αEβ7 expression in response to various stimuli in T cell cultures. 
Here, we noted that TCR stimulation alone or together with anti-CD28 caused a 
marked upregulation of αEβ7 on CD4+ and CD8+ T cells (Fig. 3A, Suppl. Fig. 3A).  
In following experiments, we assessed whether cytokines might affect αEβ7 
expression. With the exception of TGF-β, however, none of the cytokines tested had 
any effect on αEβ7 levels. Interestingly, the potential of TGF-β to induce αEβ7 was 
clearly higher in CD8+ than in CD4+ T cells (Fig. 3B). When CD4+ lymphocyte subsets 
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were analyzed, we observed that TGF-β was not able to induce αEβ7 expression on 
Th9 cells (Suppl. Fig. 3B), the subset with the highest intrinsic αEβ7 levels. This 
might be explained by the role of TGF-β in Th9 differentiation [23] in the way that 
high levels of αEβ7 on Th9 cells are a result of prior contact with TGF-β and can 
therefore not be further boosted. 
As earlier murine studies reported that TGF-β simultaneously downregulates α4β7 
[24] and the effect of α4β7-inducing retinoic acid on αEβ7 expression has not been 
tested so far, we further dissected the impact of these stimuli on the expression of 
both markers on human T cells (Suppl. Fig. 3C-F). We could demonstrate that TGF-β 
indeed reduces α4β7 expression on CD8+ but not CD4+ cells, while retinoic acid had 
no significant effect on αEβ7 levels.  
Furthermore, we assessed the effect of CCL-25, which has been shown to induce 
αEβ7 in murine CD8+ lymphocytes [25], but could not observe a similar effect in 
neither overall CD4+ and CD8+ nor FACS-purified CD4+CCR9+ and CD8+CCR9+ cells 
(Suppl. Fig. 3G). 
Finally, we incubated CD4+ and CD8+ T cells with short-chain fatty acids derived from 
microbes in the human gut [26] (Fig. 3C). While isobutyric acid and formic acid had 
no effects, low concentrations of propionic acid significantly increased αEβ7 
expression on CD4+ but not CD8+ T cells. However, we detected a significant and 
dose-dependent down-regulation of αEβ7 expression on both CD4+ and CD8+ T cells 
upon treatment with butyric acid, a key inducer of anti-inflammatory Treg cells.  
Collectively, these results showed that stimulation of T cells via the TCR, butyric acid 
and TGF-β are key regulators of αEβ7 expression. Moreover, TGF-β and TCR 
stimulation trigger a much stronger induction of αEβ7 expression on CD8+ than on 
CD4+ T lymphocytes. This is further supporting the notion that αEβ7 is especially 
important for the adhesion of CD8+ cells.  
 
Etrolizumab surrogate antibody blocks adhesion of IBD T cells to E-Cadherin 
and MAdCAM-1 more effectively than vedolizumab 
To investigate the interaction of α4β7 and αEβ7 with their ligands in vitro, we 
performed a series of adhesion assays with plates coated with E-Cadherin and/or 
MAdCAM-1. First, we employed the etrolizumab surrogate antibody FIB504 (etro-s), 
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which blocks β7 integrin, in two concentrations corresponding to the reported 
effective etrolizumab levels in human serum [27]. This antibody blocked the adhesion 
of both CD4+ and CD8+ T cells from IBD patients and control donors to E-Cadherin 
(Fig 4A, Suppl. Fig. 4E). Moreover, we tested an anti-E antibody and observed that 
this antibody was also able to block the adhesion of CD4+ and CD8+ cells to E-
Cadherin (Suppl. Fig. 4A).  
Next, we compared how vedolizumab and etrolizumab-s antibodies block the 
adhesion of lymphocytes to MAdCAM-1. Adhesion of CD4+ as well as CD8+ T cells 
from IBD patients and control donors was similarly blocked by both antibodies (Fig 
4B; Suppl. Figs 4B, E). Additionally, more untreated CD8+ T cells bound to E-
Cadherin and MAdCAM-1 compared with CD4+ cells matching which preferential 
α4β7 expression on CD8+ T cells (Suppl. Figs 4A, B). Subsequently, we coated 
slides with E-Cadherin together with MAdCAM-1. The number of adherent CD4+ and 
CD8+ cells was significantly reduced after treatment with etrolizumab-s compared 
with vedolizumab (Fig 4C; Suppl. Fig. 4C). In preparation of our in vivo experiments, 
we then coated slides with human and murine E-Cadherin. Both CD4+ and CD8+ cells 
from UC and controls bound to murine E-Cadherin in lower numbers compared with 
human E-Cadherin. However, binding still occurred to a considerable extent of 
around 70 % (Suppl. Fig. 4D) showing a marked interaction between human receptor 
and murine ligand. In conclusion, our data show that etrolizumab-s blocks the 
adhesion of human lymphocytes to both MAdCAM-1 and E-Cadherin and suggest 
that cell adhesion is reduced upon etrolizumab-s treatment compared with 
vedolizumab when both ligands are present.  
 
Superior reduction of colonic IBD CD8+ and Th9 cell accumulation in vivo upon 
treatment with etrolizumab-s compared with vedolizumab by additional 
inhibition of retention 
We next explored the functional relevance of the above mentioned interactions in 
vivo by using a humanized mouse model for analysis of T cell accumulation in the 
inflamed gut [13]. We thus induced DSS colitis in immunodeficient mice prior to 
adoptive transfer of human T cells to the ileocolic artery (Fig. 5A). Intravital confocal 
microscopy showed that CFSE-labeled CD4+ and CD8+ UC and control cells could be 
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detected in the murine lamina propria and near the epithelium (Suppl. Fig. 5A). 
Moreover, z-stacks showed the positioning of human T cells in close proximity to 
epithelial cells and confirmed extravasation (Fig. 5B, Suppl. Fig. 5B).  
Further studies confirmed that E-Cadherin is present throughout the colon of DSS-
treated mice in a pattern comparable to IBD patients (Supp. Fig. 5C). We continued 
our studies by treating CD4+ T cells from UC patients with vedolizumab, anti-CD103 
or both before adoptive transfer to DSS-treated mice. As determined by in vivo 
confocal microscopy and flow cytometry of LPMCs isolated 3h after transfer, we 
found that anti-CD103 treatment alone was not able to reduce homing of UC CD4+ 
cells and the combination of anti-CD103 with vedolizumab and vedolizumab alone 
yielded an equal reduction of colonic UC CD4+ cells (Suppl. Fig. 6A). Yet, in a similar 
series of experiments with CD8+ cells, combined blockade of α4β7 and αEβ7 through 
vedolizumab and anti-CD103 was followed by a decrease of colonic UC CD8+ cells 
compared with sole α4β7 inhibition by vedolizumab (Fig. 5D, Suppl. Fig. 6B). 
Consistently, anti-CD103 treatment also had significant effects. These results 
suggested that, while additional blockade of αEβ7 together with α4β7 might not affect 
the colonic localization of peripheral UC CD4+ cells due to their low αEβ7 expression, 
higher levels of αEβ7 on UC CD8+ cells might go along with a further reduction of 
colonic accumulation after combined blockade of both adhesion molecules. 
Before using etrolizumab-s in vivo we excluded the possibility that this antibody 
directly impacts proliferation, apoptosis or necrosis of CD4+ and CD8+ T cells (Suppl. 
Fig. 5D). Subsequently, we found that both vedolizumab and etrolizumab-s similarly 
decreased the number of colonic UC CD4+ T cells (Fig. 5C). CD8+ T cells, however, 
were found in lower numbers upon etrolizumab-s treatment compared with 
vedolizumab treatment, supporting the notion that combined α4β7 and αEβ7 
blockade might be of special relevance for CD8+ T cells (Fig. 5E).  
As αEβ7 expression is not uniformly distributed among different CD4+ T subsets, we 
reasoned that etrolizumab-s might still additionally affect certain CD4+ T subsets. 
Hence, we stained LPMCs for αEβ7 and markers of Th1, Th9 and Th17 cells, 
respectively (Figs. 5F, G, Suppl. Figs. 6C, D). Analysis of these markers on CFSE+ 
cells demonstrated that αEβ7+ cells as well as Th1, Th9 and Th17 cells were 
enriched among untreated human cells that had entered the lamina propria 
compared with aliquots from the respective donor before transfer. When comparing 
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vedolizumab and etrolizumab-s treated cells in the lamina propria, we found that the 
proportion of αEβ7+ cells was reduced upon etrolizumab-s treatment matching with its 
additional blockade of αEβ7. Concerning the CD4+ subsets, numbers of Th9 but not 
Th1 and Th17 cells were reduced with etrolizumab-s compared with vedolizumab. 
Although limited by the low number of cells analyzed, these findings prompted the 
conclusion that while the overall CD4+ T cell infiltrate was not reduced after 
etrolizumab-s compared with vedolizumab treatment, etrolizumab-s reduced the 
accumulation of Th9 cells. 
To analyze the effect that is accountable for these finding in more detail, we 
compared colonic accumulation of UC CD8+ cells 0.5 and 3 hours after adoptive 
transfer (Fig. 6). Interestingly, the effect of vedolizumab and etrolizumab-s was 
similar after 0.5h. After 3h, however, we observed similar differences as above. This 
is in line with the view that both compounds similarly inhibit α4β7-mediated homing, 
while – subsequently – etrolizumab possesses an additional and longer-lasting 
mechanism, which is easily reconcilable with the concept of inhibition of retention. 
Taken together, these results suggested that combined α4β7 and αEβ7 blockade in 
UC T cells through etrolizumab therapy results in a superior reduction of distinct 
lymphocyte subsets in the colon compared with sole α4β7 blockade through 
vedolizumab.  
To get an estimate of the potential clinical relevance of this finding, we studied the 
expression of αEβ7 on peripheral blood lymphocytes from IBD patients treated with 
vedolizumab (Figs. 7A-C). Interestingly, we observed that no changes in the 
expression of αEβ7 on CD4+ Teff and Treg cells occurred when comparing samples 
obtained during the induction phase with samples obtained during later stages of 
treatment. However, we noticed a significant increase in the expression of αEβ7 but 
not α4β7 (Fig. 7D) on CD8+ T cells in the maintenance compared with the induction 
phase suggesting that these T cells might possibly develop αEβ7-dependent 
compensatory strategies to ensure their colonic positioning despite suppression of 
gut homing via vedolizumab-induced blockade of α4β7.   
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Discussion 
 
Although clinical treatment with the monoclonal anti-α4β7 antibody vedolizumab is 
available for therapy of IBD patients for some years now, the knowledge about the 
factors that control the colonic homing and retention of lymphocytes is still 
fragmentary [28]. Particularly, this is the case for CD8+ T cells, a lymphocyte subset 
that has been largely overlooked in the past due to the prominent role of CD4+ T cells 
[4,29]. However, CD8+ T cells are thought to be not only important effector cells but 
also crucial mediators of pathologic immune responses in a number of 
immunologically mediated diseases [19,30]. Moreover, there is evidence that CD8+ T 
cells are also implicated in the events leading to human and murine colitis [5,6]. 
Using an in vivo model for IBD T cell trafficking in humanized mice, we provide 
evidence here that blockade of β7 is more effective in suppressing colonic 
accumulation of CD8+ T cells than α4β7 blockade suggesting a crucial regulatory role 
of αEβ7. Similar findings were obtained for Th9 cells, a recently identified CD4+ T cell 
subset with important pathogenic function in UC [31], but not for total CD4+ T cells. 
These results provide new insights into the molecular factors that control CD4+ and 
CD8+ T cell homing and retention in IBD patients and suggest new avenues for 
therapy. 
Interestingly, little attention has been paid to αEβ7 in the framework of IBD since its 
discovery [16] and functional in vivo data for human cells have not been reported so 
far. We uncovered that both αEβ7 and α4β7 are differentially expressed on blood and 
intestinal CD4+ and CD8+ T cells in IBD patients with higher expression on CD8+ T 
cells. The potential of TGF-β and TCR stimulation to induce αEβ7 expression was 
much higher in CD8+ than in CD4+ T cells, possibly leading to this finding. This 
observation led to the hypothesis that differential expression of adhesion markers 
might also concern CD4+ T lymphocyte subsets in IBD. Indeed, according studies 
revealed that Th9 cells bear particularly high levels of αEβ7, while Th2 and Th17 
cells had the highest expression of α4β7. Similarly, Tc9 cells expressed the highest 
levels of αEβ7 among CD8+ T cells. Collectively, these results were consistent the 
idea that clinical therapy with α4β7 or β7 blockers differentially affects distinct T 
lymphocyte subsets and might therefore have specific strengths and weaknesses in 
targeting the adhesion of these populations. This could be of potential therapeutic 
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relevance as there is fundamental evidence that different T cell subsets and their 
signature cytokines are of varying importance in individual patients [4,6,28–31].  
Compatibly, it is postulated that therapy will prospectively be assigned on the basis of 
biomarkers reflecting such immunologic profiles [35]. 
Differential expression of αEβ7 on CD4+ and CD8+ cells was demonstrated in the 
peripheral blood and the intestine of controls and IBD patients. Moreover, we show 
that both in the blood and the gut more cells can be targeted with anti-β7 than with 
anti-α4β7 antibodies. Matching with earlier reports [36] the expression of αEβ7 was 
found to be higher in the intestine than in the peripheral blood and we provide further 
evidence [37] that this is majorly due to regulation of expression and not frequency 
shifts following homing. Stimulation experiments demonstrated that mainly TGF-β 
and TCR stimulation may be responsible for this increase of αEβ7 on intestinal 
lymphocytes, while TGF-β simultaneously downregulates α4β7 on CD8+ cells. In 
conclusion, these stimuli might induce an integrin profile that allows targeting of these 
cells with etrolizumab but not vedolizumab. Moreover, butyric acid, a key inducer of 
anti-inflammatory Treg cells in the colon [26], markedly suppressed αEβ7 expression 
on both CD4+ and CD8+ T cells. Thus, it seems possible that commensal bacteria in 
close proximity to intestinal epithelial cells might affect αEβ7 levels via butyric acid 
production. 
Further stainings indicated that while DCs do not appreciably contribute to the 
population of CD8+αEβ7+ cells, the majority of these cells belongs to the 
compartment of CD69+ TRM cells. As several authors have highlighted [20,38–40], a 
subset of mainly CD8+ lymphocytes develops into resident cells that may immediately 
react to translocated antigens with cytokine secretion and thus coordinate prompt 
defense against infectious agents but might also contribute to the dysregulated 
immune response in IBD [41]. In conclusion, it is likely that TRM cells are a main 
target of anti-β7 antibodies in the intestine. To investigate the functional relevance of 
αEβ7 and α4β7 for colonic positioning in vivo, we used a recently described 
humanized mouse model [13] where DSS colitis is induced in immunodeficient mice 
prior to adoptive transfer of labeled human lymphocytes to the ileocolic artery. A 
prerequisite for assessing αEβ7 and α4β7 on human lymphocytes in this model is the 
interaction of these integrins with their respective murine ligands E-Cadherin and 
MAdCAM-1. Similarly to the described binding of human α4β7 to murine MAdCAM-1 
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[13], we found that human αEβ7 mediates adhesion to murine E-Cadherin in spite of 
reduced adhesion compared with human E-Cadherin. Moreover, confocal in vivo 
imaging after adoptive transfer of human cells demonstrated that UC T cells can be 
found in close proximity of the murine epithelium, thus allowing an interaction of 
human αEβ7 with murine E-Cadherin in vivo.  
In humanized mice, we showed that the number of UC CD4+ αEβ7+ and Th9 cells is 
reduced upon β7 blockade with the etrolizumab surrogate antibody FIB504, which 
shares the identical antigen recognition site with etrolizumab, in comparison with the 
α4β7 blocker vedolizumab. Thus, β7 blockade via the former antibody targets CD4+ 
subsets with high αEβ7 expression in UC, although the overall CD4+ T cell population 
was not affected. This is particularly interesting as we found that the expression of 
α4β7 on Th9 cells is relatively low suggesting that a considerable portion of these 
cells might be able to access the intestine despite α4β7 blockade with vedolizumab. 
Additionally targeting the epithelial retention of Th9 cells by etrolizumab might 
therefore narrow this “gap” and may be clinically relevant, as an expansion of these 
cells has been demonstrated in IBD patients and as IL-9 blockade was effective in a 
murine model of colitis induced by the hapten reagent oxazolone [31]. 
Studies using cell transfer of human T cells to DSS-treated mice showed that α4β7 
blockade via vedolizumab not only reduces the colonic homing of UC CD4+ but also 
CD8+ T cells. In addition, β7 blockade with etrolizumab-s or treatment with 
vedolizumab together with an anti-CD103 antibody further reduced the number of 
CD8+ T cells but not CD4+ T cells. Given our data on the expression and regulation of 
αEβ7 on peripheral CD4+ and CD8+ cells this may reflect the higher expression of 
αEβ7 on CD8+ T cells. Consistently, anti-CD103 antibody treatment had significant 
effects on T cell homing and retention in UC CD8+ T cells rather than CD4+ cells 
highlighting the functional relevance of αEβ7 for the former cells.  
This is in line with data from two murine studies: While Annacker et al. reported that 
αE plays no role for the pathogenic and beneficial potential of effector and regulatory 
CD4+ lymphocytes, respectively, but rather has an important regulatory role in DCs in 
the T cell transfer model of colitis [42], Lúdvíksson et al. have shown that pan-
lymphocyte inhibition of αE significantly ameliorated disease in a T cell-dependent 
colitis model [43]. 
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Different suggestions have been made regarding the concrete function of αEβ7 for 
cell trafficking. While it is known that αEβ7 interacts with the epithelial ligand E-
Cadherin and many authors have thus proposed that αEβ7 is responsible for 
retention of homed lymphocytes within or near the epithelium [16,44], αEβ7 has also 
been shown to bind to intestinal endothelial cell lines independently of E-Cadherin 
[45]. Moreover, the number of lamina propria lymphocytes is reduced in αE-deficient 
mice [46], leading to the possibility of additional direct functions for αEβ7 in gut 
homing through an alternative, yet unknown, ligand [47]. However, our reported 
findings do not provide evidence for an alternative homing via αEβ7. Importantly, 
although limited by the restricted observation period achievable in our model, our 
data provide for the first time functional in vivo evidence that αEβ7 is indeed 
implicated in the retention of human UC T cells.  
Interestingly, clinical data from UC patients treated with vedolizumab showed that 
more αEβ7, but not α4β7 is found on blood CD8+ T cells after the induction phase of 
vedolizumab therapy. This suggests that lymphocytes might use alternative 
molecules such as αEβ7 to ensure their localization within the intestine despite α4β7 
inhibition and internalization [48] by vedolizumab further supporting the concept that 
blocking αEβ7 together with α4β7 may increase the effects of anti-adhesion therapy. 
Taken together, our data suggest a key regulatory role of αEβ7 for CD8+ rather than 
global CD4+ T cell trafficking. Nevertheless, αEβ7 seems to be important in specified 
CD4+ subsets, namely Th9 cells (Figure 7D). Additional therapeutic targeting of αEβ7 
on CD8+ and Th9 cells with antibodies such as etrolizumab might therefore open new 
avenues for clinical treatment of IBD by increasing and extending the impact of sole 
α4β7 inhibition. 
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Figure legends 
 
Figure 1: Differential expression of αEβ7 and α4β7 on T cell subsets in the 
peripheral blood 
(A) Left panels: Representative flow cytometric analyses of αEβ7 (upper panels) and 
α4β7 expression (middle panels) on CD4+ and CD8+ blood lymphocytes from patients 
with UC, CD and control donors along with isotype control stainings. Numbers 
indicate the percentage of αEβ7+ and α4β7+ cells. Right panels: Pooled statistics of 
αEβ7 expression (upper panels) and α4β7 expression (lower panels) on peripheral 
blood CD4+ and CD8+ T cells from patients with UC (n = 13), CD (n = 24) and control 
donors (n = 13).  
(B)  Flow cytometry of αEβ7 and α4β7 expression on CD4+Foxp3+ (Treg), 
CD4+Foxp3- (Teff), CD4+IFN-γ+ (Th1), CD4+IL-4+ (Th2), CD4+IL-9+ (Th9) and CD4+IL-
17A+ (Th17) cells from the peripheral blood of patients with UC (n = 6-15), CD (n = 
30-44) and control donors (n = 11-21).  
 
Figure 2: Differential expression of αEβ7 and α4β7 on IBD T cell subsets in the 
lamina propria 
(A) - (C) Representative immunofluorescent stainings of cryosections from patients 
with UC, CD and control donors (n = 15-21) for CD4 (A), Foxp3 (B), CD8 (C) and 
CD103 (αE integrin, A-C) along with control stainings (A). Scale bars: 25µm (upper 
rows), 10µm (lower rows).  
(D) Quantitative analysis of the frequency of αEβ7 expression on intestinal CD4+, 
Foxp3+ and total, lamina propria and intraepithelial CD8+ T cells as indicated.  
 
Figure 3: Expression of αEβ7 is differentially regulated in T cell subsets 
(A) Left panels: Representative flow cytometric analyses of αEβ7 expression on 
CD4+ and CD8+ T cells from the peripheral blood upon stimulation with anti-CD3 
antibodies. Right panels: Flow-cytometric quantification of αEβ7 expression on CD4+ 
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and CD8+ cells upon stimulation with anti-CD3 antibodies. Values were normalized to 
the respective value before stimulation.  
(B) Flow cytometry of αEβ7 expression on CD4+ and CD8+ T cells upon stimulation 
with the indicated cytokines for 72 hours together with anti-CD3/anti-CD28 antibodies 
(n = 5-15).  
(C) Flow cytometry of αEβ7 expression on CD4+ and CD8+ T cells upon treatment 
with short chain fatty acids for 72 hours together with anti-CD3/anti-CD28 antibodies 
(n = 8-37).  
 
Figure 4: Adhesion of CD4+ and CD8+ IBD T cells to MAdCAM-1 and E-Cadherin is 
blocked by etrolizumab surrogate antibody 
(A) Upper panels: Representative adhesion assays showing the adhesion of CD4+ 
and CD8+ T cells from patients with UC and control donors to slides coated with the 
indicated ligands and control conditions without ligand. Scale bars: 25µm and 10µm 
(inserts). Lower panels: Quantitative analysis of the adhesion of CD4+ and CD8+ T 
cells from patients with UC and control donors to E-Cadherin upon treatment with 
different concentrations of etrolizumab-s.  
(B+C) Quantitative analysis of the adhesion of CD4+ and CD8+ T cells from patients 
with UC and control donors to MAdCAM-1 (B) and E-Cadherin + MAdCAM-1 (C) 
upon treatment with vedolizumab or etrolizumab-s.  
 
Figure 5: Etrolizumab surrogate antibody is more potent than vedolizumab in 
blocking the in vivo trafficking of UC CD8+ and Th9 cells 
(A) Illustration of adoptive transfer. After anesthesia, laparotomy and exposure of the 
ileocecal region, the ileocolic artery was punctured (left image) and CFSE-labelled 
human T cells were injected. Here, ink is injected to demonstrate successful puncture 
(right image). 
(B) 3D-reconstruction from a representative z-stack obtained during intravital 
confocal microscopy highlighting an extravasated human cell (green in white circle). 
Blue: murine cells. Red: murine vessels. 
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(C+E) Upper panels: Representative confocal in vivo microscopy images of murine 
colon after adoptive transfer of UC CD4+ (C) and CD8+ T cells (E) to the ileocolic 
artery. Treatment with blocking antibodies is indicated. Scale bars: 25µm (upper row) 
and 10µm (lower row). Left lower panels: Representative flow cytometry of murine 
LPMCs 3h after adoptive transfer of UC CD4+ (C) and CD8+ T cells (E). Numbers 
denote the CFSE+ cell fraction. Right lower panels: Flow-cytometric quantification of 
CFSE+ cells in the murine lamina propria 3h after adoptive transfer of UC CD4+ (C) or 
CD8+ T cells (E) in the presence or absence of integrin blockers, as indicated. Data 
were pooled from 5 independent experiments. 
(D) Left panel: Flow-cytometric quantification of CFSE+ cells in the murine lamina 
propria 3h after adoptive transfer of UC CD8+ cells upon treatment with vedolizumab 
and anti-CD103 as indicated (n = 7). Right panel: Flow-cytometric comparison of the 
colonic accumulation of untreated UC CD4+ and CD8+ T cells.  
(F) Flow-cytometric comparison of the relative portion of Th1 and Th9 cells among 
CFSE+ purified CD4+ T cells before and after transfer (n = 5-6). BT – before transfer. 
AT – after transfer. 
(G) Flow-cytometric comparison of the relative portion of Th1 and Th9 cells among 
CFSE+ purified CD4+ T cells in the murine lamina propria upon vedolizumab or 
etrolizumab-s treatment (n = 4-5). 
 
Figure 6: Time course of vedolizumab and etrolizumab-s effects – evidence for in 
vivo blockade of retention 
Upper panels: Representative intravital confocal images of murine colon at the 
indicated timepoints after adoptive transfer of UC CD8+ T cells treated with 
vedolizumab and etrolizumab-s as indicated. Scale bars: 50µm. Lower panels: Flow-
cytometric quantification of CFSE+ cells in the murine lamina propria 0.5h (left) and 
3h (right) after adoptive transfer of UC CD8+ T cells in the presence or absence of 
integrin blockers, as indicated (n = 3). 
 
Figure 7: Vedolizumab treatment leads to higher Eβ7 expression on blood IBD 
CD8+ cells 
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(A-C) Representative flow cytometric data and quantitative analyses of αEβ7 
expression on peripheral CD4+Foxp3- (A), CD4+Foxp3+ (B) and CD8+ (C) T cells 
during or after the induction phase of vedolizumab therapy as indicated.  
(D) Representative flow cytometric data and quantitative analyses of α4β7 on 
peripheral CD8+ T cells during or after the induction phase of vedolizumab therapy. 
 
Figure 8: Model for the control of colonic localization of IBD T lymphocytes by α4β7 
and αEβ7 
Cells may extravasate to the lamina propria via interaction of α4β7 with MAdCAM-1. 
Possibly, an alternative αEβ7-dependent pathway via an unknown ligand might exist. 
After homing to the intestine, interaction of αEβ7 with epithelial E-Cadherin allows 
retention of T lymphocytes in or near the epithelium. Vedolizumab blocks the 
interaction of α4β7 with MAdCAM-1, which particularly affects CD8+, Th2 and Th17 
cells, while inhibition of αEβ7 by etrolizumab is of special relevance for CD8+ and Th9 
cells.  
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Supplementary Figure 1 
(A) Exemplary gating strategy for flow cytometric assessment of α4β7 and αEβ7. 
Upper row (from left to right): After excluding doublets, lymphocytes were selected in 
the FSC-A/SSC-A plot and subsequently CD4+ and CD8+ populations were identified. 
On these populations, α4β7 and αEβ7 expression was determined (lower row). 
(B) Flow cytometry of αEβ7 on peripheral blood lymphocytes was repeated with the 
fluorochromes PE for β7 and PE/Cy7 for αE with excitement at 561nm to obtain a 
particularly bright signal. Left panels: Representative dot plots. Right panel: Pooled 
statistics of samples from control donors (n = 12), CD (n = 19) and UC (n = 9) 
patients. 
(C) Flow cytometric analysis of α4 expression on CD4+αEβ7+ and CD8+αEβ7+ cells. 
Left panels: Representative density plots. Right panel: Pooled statistics (n = 13-24). 
(D) Flow cytometry of peripheral blood lymphocytes with directly labeled vedolizumab 
and etrolizumab-s. Upper panels: Representative stainings from control (n = 10), UC 
(n = 10) and CD (n = 27) patients along with isotype control stainings. Lower panels: 
Pooled statistics of the frequency of vedolizumab+etrolizumab-s+ double positive cells 
and vedolizumab-etrolizumab-s+ single positive cells among CD4+ and CD8+ cells as 
wells percentage of vedolizumab-etrolizumb-s+ single positive cells among total 
etrolizumab-s+ cells.  
(E) Left panels: Representative flow cytometric cytokine stainings for IFN-γ, IL-4, IL-9 
and IL-17A in CD4+ cells from the peripheral blood from patients with CD, UC and 
control donors along with negative control stainings. To induce cytokine production, 
cells were stimulated with anti-CD3/anti-CD28 overnight before restimulation with 
PMA/ionomycin and transport inhibition by brefeldin A for four hours. Right panels: 
Quantification of cytokine-positive CD4+ cells in the peripheral blood from patients 
with CD, UC and control donors.   
(F) Representative dot plots showing the expression of αEβ7 (upper panels) and 
α4β7 (lower panels) on the gated CD4+ subsets of Treg (Foxp3+), Teff (Foxp3-), Th1 
(IFN-γ+), Th2 (IL-4+), Th9 (IL-9+) and Th17 (IL-17A+) cells.  
(G) Flow cytometry of αEβ7 and α4β7 expression on CD4+Foxp3+ (Treg), 
CD4+Foxp3- (Teff), CD4+IFN-γ+ (Th1), CD4+IL-4+ (Th2), CD4+IL-9+ (Th9) and CD4+IL-
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17A+ (Th17) cells from the peripheral blood of patients with UC (n = 6-15), CD (n = 
30-44) and control donors (n = 11-21). 
(H+ I) Flow cytometry of αEβ7 and α4β7 expression on CD8+IFN-γ+ (Tc1), CD8+IL-4+ 
(Tc2), CD8+IL-9+ (Tc9) and CD8+IL-17A+ (Tc17) cells from the peripheral blood of 
patients with UC (n = 10), CD (n = 19) and control donors (n = 13). 
 
Supplementary Figure 2 
(A) Absolute numbers of CD4+ and/or CD103+ single- or double-positive cells in the 
immunohistochemistry stainings shown in Fig. 2A+D. 
(B) Absolute numbers of Foxp3+ and/or CD103+ single- or double-positive cells in the 
immunohistochemistry stainings shown in Fig. 2B+D. 
(C) Absolute numbers of CD8+ and/or CD103+ single- or double-positive cells in the 
immunohistochemistry stainings shown in Fig. 2C+D. 
(D) Left panels: Representative immunohistochemistry stainings of frozen 
cryosections from control, UC and CD patients (n = 12) for CD69 and CD103. Right 
upper panel: Frequency of CD103+ cells among CD69+ cells. Right lower panels: 
Frequency of CD8+ (left) and CD69+ (right) cells among CD103+ cells.  
(E) Left panels: Representative immunohistochemistry stainings of frozen 
cryosections from control, UC and CD patients (n = 12) for CD11c and CD103. Right 
panel: Frequency of CD103+ cells among CD11c+ cells. 
(F) Left panels: Representative immunohistochemistry stainings of frozen 
cryosections from control, UC and CD patients (n = 12) for CD8 and CD11c. Right 
panel: Frequency of CD8+ cells among CD11c+ cells. 
(G) Left panels: Representative immunohistochemistry stainings of frozen 
cryosections from control, UC and CD patients (n = 15) for CD123 and CD103. Right 
panel: Frequency of CD103+ cells among CD123+ cells. 
(H) Left panels: Representative immunohistochemistry stainings of frozen 
cryosections from control, UC and CD patients (n = 15) for CD141 and CD103. Right 
panel: Frequency of CD103+ cells among CD141+ cells. 
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(I) Left panels: Representative immunohistochemistry stainings of frozen 
cryosections from control, UC and CD patients (n = 12) with vedolizumab and 
etrolizumab-s. Examples of etrolizumab single-positive and vedolizumab/etrolizumab-
s double-positive cells are marked with white and orange arrows, respectively. Right 
panels: Absolute number of vedo+etro-s+ double positive cells and vedo-etro-s+ single 
positive cells and frequency of etro-s single positive cells among total etro-s+ cells. 
 
Supplementary Figure 3 
(A) Quantitative flow cytometry of αEβ7 expression on CD4+ and CD8+ cells upon 
stimulation with anti-CD3 and/or anti-CD28 antibodies (n = 4-8). Values were 
normalized to the respective value before stimulation. 
(B) Flow cytometry of αEβ7 expression on Treg (CD4+Foxp3+), Teff (CD4+Foxp3-), 
Th1 (CD4+IFN-γ+), Th2 (CD4+IL-4+), Th9 (CD4+IL-9+) and Th17 (CD4+IL-17A+) cells 
upon stimulation with the indicated cytokines for 72 hours together with anti-CD3/anti-
CD28 antibodies (n = 5-15).  
(C) Left panels: Representative flow cytometric analyses of integrin α4, β7 and αE 
positivity of CD4+ and CD8+ cells following incubation with (red lines) or without (blue 
lines) TGF-β together with anti-CD3/CD28 antibodies for 72 hours. Right panels: 
Mean fluorescence intensity of α4, β7 and αE on CD4+ and CD8+ cells following 
incubation with or without TGF-β together with anti-CD3/CD28 antibodies for 72 
hours (n = 8). 
(D) Representative dot plots and flow cytometric quantification of α4β7 (left panels) 
and αEβ7 expression (right panels) on CD4+ and CD8+ cells following incubation with 
or without TGF-β together with anti-CD3/CD28 antibodies for 72 hours (n = 8). 
(E) Left panels: Representative flow cytometric analyses of integrin α4, β7 and αE 
positivity of CD4+ and CD8+ cells following incubation with (red lines) or without (blue 
lines) retinoic acid (RA) together with anti-CD3/CD28 antibodies for 72 hours. Right 
panels: Mean fluorescence intensity of α4, β7 and αE on CD4+ and CD8+ cells 
following incubation with or without RA together with anti-CD3/CD28 antibodies for 72 
hours (n = 8). 
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(F) Representative dot plots and flow cytometric quantification of α4β7 (left panels) 
and αEβ7 expression (right panels) on CD4+ and CD8+ cells following incubation with 
or without RA together with anti-CD3/CD28 antibodies for 72 hours (n = 8). 
(G) Upper panels: Flow cytometry of αEβ7 expression on CD4+ and CD8+ T cells 
upon treatment with different concentrations of CCL-25 together with anti-CD3/anti-
CD28 antibodies for 72 hours (n = 11). Lower panels: Flow cytometry of αEβ7 
expression on FACS-purified CD4+CCR9+ and CD8+CCR9+ T cells upon treatment 
with different concentrations of CCL-25 together with anti-CD3/anti-CD28 antibodies 
for 72 hours (n = 4) 
 
Supplementary Figure 4: 
(A) Left and middle panel: Quantitative analysis of the adhesion of CD4+ and CD8+ 
cells from patients with UC and control donors to E-Cadherin upon treatment with the 
anti-CD103 antibody used for the experiments shown in Fig. 5D and Suppl. Fig. 
6A+B (n = 5). Right panel: Comparison of the adhesion of untreated CD4+ and CD8+ 
cells to E-Cadherin (n = 7). 
(B+C) Upper panels: Representative adhesion assays showing the adhesion of CD4+ 
and CD8+ T cells from patients with UC and control donors to slides coated with the 
indicated ligands and control conditions without ligand. Scale bars: 25µm and 10µm 
(inserts). Lower panels: Comparison of the adhesion of untreated CD4+ and CD8+ 
cells to the indicated ligands (n = 7-10). 
(D) Left panels: Representative adhesion assays showing the adhesion of CD4+ and 
CD8+ T cells from patients with UC and control donors to slides coated with human 
and murine E-Cadherin and control conditions without ligand. Scale bars: 25µm and 
10µm (inserts). Right panels: Quantitative analysis of the adhesion of CD4+ and 
CD8+ cells to human and murine E-Cadherin (n = 5). 
(E) Quantitative analysis of the adhesion of CD4+ and CD8+ cells from patients with 
CD to E-Cadherin (upper panels), MAdCAM-1 (middle panels) and E-Cadherin + 
MAdCAM-1 (lower panels) upon treatment with vedolizumab and etrolizumab-s as 
indicated (n = 3-4). 
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Supplementary Figure 5 
(A) Intravital confocal microscopy of murine colon after adoptive transfer of CFSE-
labeled CD4+ and CD8+ T cells to the ileocolic artery. Additionally, Hoechst dye and 
Texas Red Dextran were injected to stain murine cells (blue) and vessels (red), 
respectively. Human cells (green) can be observed within the murine lamina propria 
and near the epithelium. Scale bars: 50µm and 10µm (inserts). 
(B) Upper row: Representative confocal in vivo images from a z-stack at the indicated 
relative positions highlighting an area containing an extravasated cell (white circle). 
Scale bars: 50µm. Lower row: 3D reconstruction of the z-stack showing single 
channels and the merged image.  
(C) Representative immunofluorescent stainings of murine (left panels) and human 
(right panels) cryosections for E-Cadherin along with a control staining of murine 
colon. Scale bars: 25µm and 10µm (magnifications). Murine samples come from 
DSS-treated NSG mice, human samples from UC and CD patients as indicated.  
(D) Proliferation, apoptosis and necrosis of CD4+ (upper panels) and CD8+ cells 
(lower panels) upon treatment with the indicated concentrations of etrolizumab 
surrogate antibody for 72 hours together with anti-CD3, anti-CD28 and IL-2 (n = 8).  
 
Supplementary Figure 6 
(A) Upper panels: Representative confocal in vivo microscopy images of murine 
colon after adoptive transfer of UC CD4+ T cells to the ileocolic artery. Treatment with 
blocking antibodies is indicated. Scale bars: 25µm (upper row) and 10µm (lower row). 
Middle panels: Representative flow cytometry of murine LPMCs 3h after adoptive 
transfer of UC CD4+ and CD8+ T cells. Numbers denote the CFSE+ cell fraction. 
Lower panels: Flow-cytometric quantification of CFSE+ cells in the murine lamina 
propria 3h after adoptive transfer of UC CD4+  T cells in the presence or absence of 
integrin blockers, as indicated. Data were pooled from 7 independent experiments. 
(B) Upper panels: Representative confocal in vivo microscopy images of murine 
colon after adoptive transfer of UC CD8+ T cells to the ileocolic artery. Treatment with 
blocking antibodies is indicated. Scale bars: 25µm (upper row) and 10µm (lower row). 
Middle panels: Representative flow cytometry of murine LPMCs 3h after adoptive 
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transfer of UC CD4+ and CD8+ T cells. Numbers denote the CFSE+ cell fraction. 
Pooled statistics are shown in the left panel of Fig. 6D. 
(C) Comparison of the relative portion of αEβ7 and Th17 cells among CFSE+ purified 
CD4+ T cells before and after transfer (n = 5).  
(D) Comparison of the relative portion of αEβ7 and Th17 cells among CFSE+ purified 
CD4+ T cells in the murine lamina propria upon vedolizumab or etrolizumab-s 
treatment (n = 3-4). 
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